drugset / Trial / NCT00019721
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have metastatic melanoma that has not responded to previous therapy.
Timeline
- Start
- 1999-04
- Primary completion
- —
- Completion
- 2003-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MART-1 antigen | Vaccine | — | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |